Kiniksa Pharmaceuticals International (KNSA) Change in Cash (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Change in Cash for 10 consecutive years, with -$14.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Cash fell 140.9% year-over-year to -$14.3 million; the trailing twelve-month figure through Jun 2026 stood at -$16.4 million (down 117.64% YoY), and the FY2025 full-year result was -$18.0 million, down 123.78% from the prior year.
• Change in Cash retreated to -$14.3 million in Q2 2026 per KNSA's latest filing, from $24.4 million in the prior quarter.
• Across five years, Change in Cash topped out at $86.2 million in Q4 2024 and bottomed at -$59.1 million in Q1 2022.
• Historically, Change in Cash has averaged $3.0 million across 5 years, with a median of -$5.6 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Change in Cash sank 1116.6% in 2022, then surged 973.05% in 2024.
• Over 5 years, Change in Cash stood at -$53.0 million in 2022, then surged by 81.39% to -$9.9 million in 2023, then soared by 973.05% to $86.2 million in 2024, then plunged by 110.74% to -$9.3 million in 2025, then slumped by 54.12% to -$14.3 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$14.3 million, $24.4 million, and -$9.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.